Procaps Group and Genomma Lab Internacional, S.A.B. de C.V. announced a strategic agreement to develop, manufacture and market five Softgel products within Latin America. Through this partnership, Procaps will manufacture and Genomma will market and distribute the products.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.82 USD | -5.05% | +3.41% | -30.71% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
16.66 MXN | -1.88% | +2.21% | 910M | ||
2.82 USD | -5.05% | +3.41% | 318M | ||
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-30.71% | 318M | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- PROC Stock
- News Procaps Group S.A.
- Procaps Group and Genomma Lab Announce Strategic Agreement to Manufacture and Market Softgel Products in Latin America